PMEL and glomus tumor: IHC profiling is essential, as glomus tumors typically express markers such as vimentin, SMA, calponin, actin, desmin, and CD34, while GLI1‐altered mesenchymal tumors may exhibit positivity for vimentin, S100, CD56, cyclinD1, and negativity for SOX10, SMA, melan‐A, HMB‐45, synaptophysin, and a variety of other markers, indicating significant immunospectrum shifts [40].